Key Players
Competitive Landscape
Companies competing in the Usher syndrome market include cochlear implant manufacturers and hearing-aid groups alongside inherited-retinal drug developers and ocular gene-therapy specialists.
Investment has shifted in two directions from 2025 onward, toward implant-assisted drug delivery and retinal programs built around exact genetic eligibility. Advanced Bionics announced its Spiral Therapeutics collaboration in April 2026, connecting cochlear surgery with research on precision inner-ear drug delivery. The collaboration places implant manufacturers closer to local therapeutic-delivery research without changing current device-based care. AAVantgarde completed LUCE-1 enrollment in January 2026, advancing a dual-vector MYO7A program through its first adult clinical cohort. The enrollment milestone shifts MYO7A competition from vector design into clinical execution and repeated retinal follow-up. Competition now turns on service reach, genotype fit and clinical maturity across separate auditory and retinal pathways.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Advanced Bionics equity investment and Spiral Therapeutics research collaboration, April 2026 | Implant centers need drug delivery that fits established surgical and follow-up routes. | Cochlear implant platforms are adding therapeutic-delivery research. | Precision inner-ear delivery during implantation. |
| AAVantgarde completed LUCE-1 enrollment of 15 adults, January 2026 | Retinal centers need a viable delivery route for the oversized MYO7A gene. | Dual-vector gene therapy has entered human testing for USH1B. | Clinical delivery for mutation-confirmed adults. |
| Nacuity reported more than 50% lower photoreceptor loss over two years, September 2025 | Retinal clinics need treatment options that do not depend on one causal mutation. | Gene-agnostic oral programs are advancing beside mutation-specific therapy. | Confirmatory development of a self-administered retinal treatment. |
Established hearing-care competition includes Cochlear Limited alongside MED-EL and WS Audiology, whereas Laboratoires Théa and Atsena Therapeutics pursue retinal programs without a dated Usher-specific announcement from January 2025 onward.
Source: Future Market Insights, Usher Syndrome and Inherited Retinal Diseases Treatment Market Reports, 2026-2036.
Cochlear Limited and Advanced Bionics cover cochlear implantation alongside MED-EL, whereas WS Audiology supports hearing-aid fitting and therapy developers address USH2A or MYO7A plus gene-agnostic retinal pathways.
Which companies provide established hearing intervention for people with Usher syndrome?
Cochlear Limited, Advanced Bionics and MED-EL provide marketed cochlear implant systems with clinical fitting and rehabilitation support. WS Audiology adds hearing-aid fitting through Widex and other brands for people who retain useful residual hearing.
Which companies have exact Usher retinal programs in human studies?
Laboratoires Théa sponsors the Phase 2b LUNA study of ultevursen for USH2A exon 13 variants. Nacuity and AAVantgarde have completed clinical enrollment milestones for gene-agnostic oral therapy and dual-vector USH1B treatment.
Which companies target MYO7A-associated Usher syndrome type 1B?
AAVantgarde evaluates AAVB-081 in Phase 1/2 testing for adults with molecularly confirmed MYO7A-associated Usher syndrome type 1B.
Which companies support fitting and follow-up across major regions?
Cochlear Limited, Advanced Bionics and MED-EL combine implant systems with clinical support across major commercial regions. Repeated imaging and mutation screening concentrate retinal trial delivery in tertiary centers, so therapy developers rely on multicountry sites or specialist partners.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Cochlear Limited | Global | Marketed cochlear implants and the Nucleus Nexa system launched in July 2025. |
| Advanced Bionics AG | Global | Cochlear implant systems plus an April 2026 research collaboration on precision inner-ear drug delivery. |
| MED-EL | Global | Cochlear implants and rehabilitation support with a United States indication from seven months of age. |
| WS Audiology A/S | Global | Widex hearing aids and cloud-based fitting software for hearing-care professionals. |
| Laboratoires Théa (Sepul Bio) | Multicountry clinical network | Phase 2b ultevursen program for USH2A exon 13 variants. |
| Nacuity Pharmaceuticals | United States and Australia | Oral NPI-001 program for retinitis pigmentosa associated with Usher syndrome. |
| Atsena Therapeutics | United States and partners | IND-ready ATSN-301 dual-vector program for MYO7A-associated USH1B. |
| AAVantgarde Bio s.r.l. | Europe and multicountry trial | Phase 1/2 AAVB-081 dual-vector program for MYO7A-associated USH1B. |
Research Methodology
The companies here show how the Usher syndrome market is structured without ranking participants by revenue or total corporate scale. Inclusion requires current public evidence of hearing intervention or an exact Usher-associated retinal program tied to the named company. Official company releases and clinical registries support dated actions, while regulatory records and corporate disclosures establish current capability or geographic scope. The 52.0% type 2 figure remains an FMI proprietary estimate for 2026 and does not measure company share.
